



(51) International Patent Classification:

C07K 16/30 (2006.01) G01N 33/53 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)
A61K 47/68 (2017.01) C12N 15/62 (2006.01)
A61K 51/10 (2006.01)

(21) International Application Number:

PCT/US2023/069710

(22) International Filing Date:

06 July 2023 (06.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/367,953 08 July 2022 (08.07.2022) US

(71) Applicant: IMAGINAB, INC. [US/US]; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US).

(72) Inventors: MASCIONI, Alessandro; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). JIA, Fang; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). DE SOUZA, CORDEIRO, Leticia, Maria; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). ATKINSON, Kelley, C.; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). JOYCE, Patrick;

423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). AIVAZIAN, Argin; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US).

(74) Agent: LOZAN, Vladimir, S.; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: DLL3 ANTIGEN BINDING CONSTRUCTS

FIG. 10

Binding to tumor cells (Flow Cytometry):



(57) Abstract: Provided herein are components for antigen binding constructs, including antibodies and fragments thereof, such as minibodies and cys-diabodies, that bind to a target molecule, for example, DLL3. In some embodiments, these components are novel complementarity-determining region (CDR) sequences and/or sequences associated with and/or part of the CDR sequence. In some embodiments, these components are novel framework region (FR) sequences and/or sequences associated with and/or part of the FR sequence. These CDR and FR sequences can provide various benefits. Also provided herein are the antigen binding constructs (such as, minibodies, cys-diabodies, etc.) that include one or more of the CDR or FR sequences or subsequences provided herein.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

17 October 2024 (17.10.2024)